CareDx/$CDNA
1D1W1MYTD1Y5YMAX
Capital at risk
About CareDx
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
- Ticker
- $CDNA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 763
- Headquarters
- Brisbane, United States
- Website
- caredx.com
CareDx Metrics
BasicAdvanced
$3.4B
31.24
$2.12
2.43
-
Price and volume
Market cap
$3.4B
Beta
2.43
52-week high
$67.29
52-week low
$13.95
Average daily volume
1.3M
Financial strength
Current ratio
4.581
Quick ratio
4.355
Long term debt to equity
0.031
Total debt to equity
0.045
Profitability
EBITDA (TTM)
12.433
Gross margin (TTM)
70.58%
Net profit margin (TTM)
24.23%
Operating margin (TTM)
-0.43%
Effective tax rate (TTM)
3.63%
Revenue per employee (TTM)
$600,000
Management effectiveness
Return on assets (TTM)
-0.25%
Return on equity (TTM)
29.49%
Valuation
Price to earnings (TTM)
31.238
Price to revenue (TTM)
7.453
Price to book
8.01
Price to tangible book (TTM)
9.19
Price to free cash flow (TTM)
40.632
Free cash flow yield (TTM)
2.46%
Free cash flow per share (TTM)
1.63
Growth
Revenue change (TTM)
34.41%
Earnings per share change (TTM)
112.54%
3-year revenue growth (CAGR)
13.99%
10-year revenue growth (CAGR)
30.86%
3-year earnings per share growth (CAGR)
10.51%
10-year earnings per share growth (CAGR)
-0.85%
What the Analysts think about CareDx
Analyst ratings (Buy, Hold, Sell) for CareDx stock.
Analyst projections of the future price of CareDx stock.
Bulls say / Bears say
CareDx is converting adoption into strong operating growth: second-quarter revenue rose 52%, Testing Services revenue rose 61%, and test volume increased 17%. Management then raised 2026 revenue guidance to $490 million–$500 million and adjusted EBITDA guidance to $66 million–$78 million. (CareDx)
The final Medicare policy preserves coverage for AlloSure Kidney, AlloMap, AlloSure Heart and AlloSure Lung, with more generous surveillance limits than the earlier proposal. This removes a major near-term threat to access and allowed management to remove a previously expected $7.5 million LCD headwind from its outlook. (CareDx, GenomeWeb)
CareDx is broadening its growth opportunity beyond its established transplant tests. New clinical evidence supports AlloSure across several transplant settings, while the NavDx acquisition adds a specialty-oncology platform and AlloHeme and HistoMap Kidney provide further pipeline potential. (CareDx, CareDx)
Medicare and policy remain material risks despite the favourable LCD outcome. The final rules impose frequency limits, and recent Medicare pricing pressure shows that coverage does not guarantee stable revenue per test. (CareDx, EveryTicker)
Headline Testing Services growth overstates the underlying run rate because second-quarter revenue included $15.6 million from tests performed in earlier periods. CareDx said comparable Testing Services growth excluding this recognition was about 28%, well below the reported 61%. (CareDx)
The NavDx expansion adds execution and capital-allocation risk while the business is still being integrated. CareDx paid about $161.8 million upfront, with up to $100 million of earn-outs, and its 2026 guidance relies on specialty-oncology revenue arriving in the second half of the year. (StockTitan, CareDx)
Data summarised monthly by Lightyear AI. Last updated on 24 Sept 2026.
CareDx Financial Performance
Revenues and expenses
CareDx Earnings Performance
Company profitability
Upcoming events
No upcoming events
CareDx News
AllArticlesVideos
Funds containing CareDx
AllUSDEURGBP
Fund name | Fund size | $CDNA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.31% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.31% |
iShares Healthcare Innovation£DRDR | £1B | 0.31% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.11% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.